Zug, Switzerland

Angiotech International Ag

USPTO Granted Patents = 7

% Expired Patents = 85.7


Trademarks = 1

Forward Citations = 554

Loading Chart...
Loading Chart...

11 inventors (with patents filed for the assignee):

goldMedal Philip Michael Toleikis (7 out of 17 patents)

silverMedal David M Gravett (6 out of 26 patents)

bronzeMedal William L Hunter (5 out of 67 patents)

4.  Richard Tom Liggins (4 out of 11 patents)

5.  Troy A E Loss (3 out of 3 patents)

6.  Dechi Guan (2 out of 10 patents)

7.  Arpita Maiti (2 out of 2 patents)

8.  Aniko Takacs-Cox (1 out of 6 patents)

9.  Leanne Embree (1 out of 1 patent)

10.  Rui Avelar (1 out of 5 patents)

11.  Pierre E Signore (1 out of 1 patent)

12.  David M Gravett (0 patent)

13.  T Richard Liggins (0 patent)


7 patents:

Company Overview
Angiotech International Ag is a global pioneer in the development, manufacturing, and marketing of innovative medical devices and pharmaceuticals. With a focus on improving patient outcomes, Angiotech's products are used in a variety of medical specialties including surgery, interventional cardiology, and dermatology. The company's commitment to research and development ensures that they remain at the forefront of medical technology, providing healthcare professionals with cutting-edge solutions to improve patient care.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

7 Patents

#71 in

#1,340 in

Zug, CH
Zug, Switzerland
Forward Citations = 554

11 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Angiotech International Ag. Retrieved from https://idiyas.com/company/angiotech-international-ag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…